Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662D F Hayes, H Yamauchi, G Broadwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patientsC L Shapiro, L Ayash, I J Webb, et al.
British Journal of Cancer|December 3, 2009
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapyN L Henry, A Nguyen, F Azzouz, et al.
The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)P Sharma, W E Barlow, A K Godwin, et al.
The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.
Nature Medicine|December 1, 1996
Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cellsC D Gimmi, B W Morrison, B A Mainprice, et al.
Journal of the National Cancer Institute|October 16, 1996
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markersD F Hayes, R C Bast, C E Desch, et al.
Pageof 13